Key result
Glucocorticoid receptor antagonism boosts regenerative growth factors, improving post-injury cardiac function.
Why the study?
Myocardial injuries cause cardiomyocyte loss and heart failure, and endogenous glucocorticoids limit cardiomyocyte regeneration via the glucocorticoid receptor.
Does glucocorticoid receptor antagonism enhance the efficacy of cardiac regenerative growth factors in murine models of myocardial injury?
Does glucocorticoid receptor antagonism enhance the efficacy of cardiac regenerative growth factors in murine models of myocardial injury?
Glucocorticoid receptor antagonism removes a postnatal systemic brake on cardiomyocyte proliferation, enhancing the efficacy of growth-factor-based regenerative therapies in preclinical models.
Should not yet change practice; extends evidence that GR antagonism removes a postnatal brake on cardiomyocyte proliferation.
Myocardial injuries lead to cardiomyocyte loss and heart failure. Endogenous glucocorticoids, via the glucocorticoid receptor (GR), limit cardiomyocyte regeneration. Here we show that glucocorticoids suppress mammalian (murine) cardiomyocyte proliferative response to regenerative growth factors and cytokines. GR activation in neonatal cardiomyocytes upregulated MAPK-ERK inhibitors ERRFI1 and DUSP1. Using neuregulin 1 as a model, we demonstrated that glucocorticoids inhibit growth-factor-induced ERK activation, nuclear translocation and transcriptional output. Errfi1 and Dusp1 knockdown restored growth-factor-induced proliferation of glucocorticoid-exposed cardiomyocytes. Cardiac expression of DUSP1 and ERRFI1 increased postnatally, coinciding with regenerative capacity decline. In juvenile and adult cardiomyocytes, regenerative growth factors failed to induce the MAPK-ERK pathway and proliferation; however, DUSP1 inhibition restored these responses. GR antagonism enhanced growth-factor-induced cardiomyocyte protection, proliferation and cardiac function after adult myocardial injury. These findings reveal the emergence of a postnatal systemic brake on cardiomyocyte proliferative response to growth factors and support GR inhibition as a strategy to enhance growth-factor-based regenerative therapies.
No takes yet. Share an insight, caveat, or question.
Pra et al. (2026) studied this question. Glucocorticoid receptor antagonism enhances the efficacy of regenerative growth factors, improving cardiomyocyte protection, proliferation, and cardiac function after adult myocardial injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: